

<b>Pathway:</b>	Resperate® (Intercure Ltd)
<b>Referral Criteria/Commissioning position:</b>	
<p>NHS Scarborough &amp; Ryedale Clinical Commissioning Group (SRCCG) does not commission the use of the Resperate® device for the treatment of hypertension owing to inadequate evidence of long term benefit over other relaxation techniques.</p> <p>As such, clinicians should not routinely prescribe or recommend this product to patients either as monotherapy or an adjunct to pharmacological management because there is limited clinical evidence of effectiveness.</p> <p>Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. Individual cases will be reviewed as per the CCG policy.</p>	
<b>Investigations prior to referral</b>	
<ul style="list-style-type: none"> <li>• None</li> </ul>	
<b>Information to include in referral letter:</b>	
<b>References &amp; Additional information:</b>	
<p>For the full SRCCG commissioning policy please <a href="#">click here</a></p> <p><b>References:</b></p> <ol style="list-style-type: none"> <li>1. Mahtani KR, Nunan D, Heneghan CJ. Device-guided breathing exercises in the control of human blood pressure: systematic review and meta-analysis. Journal of Hypertension 2012; 30(5):852-860 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22495126">http://www.ncbi.nlm.nih.gov/pubmed/22495126</a></li> <li>2. Meta-analysis of the RESPeRATE device for lowering BP and related statement from the British Hypertension Society. (April 2012) <a href="http://www.bhsoc.org/pdfs/Statement%20on%20RESPeRATE%20April%2012.pdf">http://www.bhsoc.org/pdfs/Statement%20on%20RESPeRATE%20April%2012.pdf</a></li> </ol>	
<b>CCG GP sign off:</b>	SRCCG Business Committee (December 2015)
<b>Review date:</b>	2017